Psylocibin-assisted therapy could become a more successful treatment for mood disorders in patients with terminal illnesses than currently approved treatments
Clinicians prescribe medications such as antidepressants and other approved pharmacological resources that seem to be not completely significant, as there are further considerations that prevent the longevity of use as well as the withdrawal factor. In addition, factors such as the increased risk of attempting suicide which is presented in antidepressants are not reported in clinical trials in which psilocybin is used.
0
1
References
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review. Int Rev Psychiatry
Tags
Behavioral Neuroscience
Psychology
Neuroscience (Neurobiology)
Social Science
Empirical Science
Science
Life Science / Biology
Biomedical Sciences
Natural Science
Health Psychology
SARS-CoV-2 (COVID-19)
Related
Psilocybin – summary of knowledge and new perspectives. European Neuropsychopharmacology,
Psylocibin-assisted therapy could become a more successful treatment for mood disorders in patients with terminal illnesses than currently approved treatments
Psylocibin-assisted therapy could become a more successful treatment for mood disorders in patients with terminal illnesses than currently approved treatments